CEL-SCI Corp (CVM):企業の財務・戦略的SWOT分析

◆英語タイトル:CEL-SCI Corp (CVM) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1097
◆発行会社(調査会社):GlobalData
◆発行日:2020年2月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

CEL-SCI Corp (CVM) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

CEL-SCI Corp (CEL-SCI) is a biotechnology company that carries out the research and development of new immunotherapy products for the treatment of various cancer and infectious diseases. Its core capabilities include drug discovery, research, development and manufacturing of compound biological substances. CEL-SCI’s lead candidate Multikine (leukocyte interleukin), is an investigational immunotherapy against cancer and human papilloma virus (HPV). The company is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 in hospitalized patients and vaccines CEL-2000 and CEL-4000 for rheumatoid arthritis using Ligand Epitope Antigen Presentation System (LEAPS) technology platform. CEL-SCI is headquartered in Vienna, Virginia, the US.

CEL-SCI Corp Key Recent Developments

Feb 10,2020: CEL-SCI reports first quarter fiscal 2020 financial results
Dec 16,2019: CEL-SCI reports fiscal 2019 financial results and clinical & corporate developments
Aug 14,2019: CEL-SCI reports third quarter fiscal 2019 financial results
May 14,2019: CEL-SCI announces second quarter fiscal 2019 financial results
Mar 04,2019: CEL-SCI’s scientific article on vaccines for autoimmune disease published in Journal of Clinical & Cellular Immunology

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
CEL-SCI Corp – Key Facts
CEL-SCI Corp – Key Employees
CEL-SCI Corp – Key Employee Biographies
CEL-SCI Corp – Major Products and Services
CEL-SCI Corp – History
CEL-SCI Corp – Company Statement
CEL-SCI Corp – Locations And Subsidiaries
Head Office
Section 2 – Company Analysis
Company Overview
CEL-SCI Corp – Business Description
CEL-SCI Corp – Corporate Strategy
CEL-SCI Corp – SWOT Analysis
SWOT Analysis – Overview
CEL-SCI Corp – Strengths
CEL-SCI Corp – Weaknesses
CEL-SCI Corp – Opportunities
CEL-SCI Corp – Threats
CEL-SCI Corp – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
CEL-SCI Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 10, 2020: CEL-SCI reports first quarter fiscal 2020 financial results
Dec 16, 2019: CEL-SCI reports fiscal 2019 financial results and clinical & corporate developments
Aug 14, 2019: CEL-SCI reports third quarter fiscal 2019 financial results
May 14, 2019: CEL-SCI announces second quarter fiscal 2019 financial results
Mar 04, 2019: CEL-SCI’s scientific article on vaccines for autoimmune disease published in Journal of Clinical & Cellular Immunology
Feb 14, 2019: CEL-SCI reports first quarter fiscal 2019 financial results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
CEL-SCI Corp, Key Facts
CEL-SCI Corp, Key Employees
CEL-SCI Corp, Key Employee Biographies
CEL-SCI Corp, Major Products and Services
CEL-SCI Corp, History
CEL-SCI Corp, Key Competitors
CEL-SCI Corp, Ratios based on current share price
CEL-SCI Corp, Annual Ratios
CEL-SCI Corp, Annual Ratios (Cont...1)
CEL-SCI Corp, Interim Ratios
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
CEL-SCI Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
CEL-SCI Corp, Performance Chart (2015 - 2019)
CEL-SCI Corp, Ratio Charts
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[CEL-SCI Corp (CVM):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Taejoon Pharm Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Taejoon Pharm Co Ltd (Taejoon) is a pharmaceutical company that markets ophthalmic agents and other drugs. The company offers injections, powders, eye drops, spray, syrups, tablets, soft capsules, liquids for external use, and hard capsules. Its powder products comprise coolprep powder, taej …
  • Zoll Medical Corporation-医療機器分野:企業M&A・提携分析
    Summary ZOLL Medical Corporation (Zoll), a subsidiary of Asahi Kasei Corporation, is a provider of medical devices and software solutions for advance emergency care. The company designs, manufactures and markets resuscitation devices and systems used for resuscitation and acute critical care victims …
  • Achaogen Inc (AKAO):企業の財務・戦略的SWOT分析
    Summary Achaogen Inc (Achaogen) is a biopharmaceutical company that discovers, develops and commercializes novel antibacterial treatments for the treatment of multi-drug resistant and gram-negative infections. The company’s lead product, plazomicin used for the treatment of serious bacterial infecti …
  • SK Telecom Co., Ltd.:企業の戦略・SWOT・財務分析
    SK Telecom Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary SK Telecom Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Rossiiskie Zheleznye Dorogi:企業の戦略・SWOT・財務情報
    Rossiiskie Zheleznye Dorogi - Strategy, SWOT and Corporate Finance Report Summary Rossiiskie Zheleznye Dorogi - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • China High Speed Transmission Equipment Group Co Ltd (658):電力:M&Aディール及び事業提携情報
    Summary China High Speed Transmission Equipment Group Co Ltd (CHSTE), a subsidiary of Five Seasons XVI Ltd, specializes in the production of high-speed and heavy-load transmission equipment. The company carries out research, design, development, manufacture and distribution of a broad range of mecha …
  • Dai Nippon Printing Co Ltd (7912):企業の財務・戦略的SWOT分析
    Dai Nippon Printing Co Ltd (7912) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Symbiotec Pharmalab Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Symbiotec Pharmalab Ltd (Symbiotec) is a medical laboratory that manufactures active pharmaceutical ingredients. The laboratory develops, produces and markets research-based cortico steroids and steroid-hormone APIs. Its cortico-steroids APIs include clobetasol propionate, betamethasone dipr …
  • CRH public limited company (CRG):企業の財務・戦略的SWOT分析
    CRH public limited company (CRG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • The Wendy’s Company:戦略・SWOT・企業財務分析
    The Wendy’s Company - Strategy, SWOT and Corporate Finance Report Summary The Wendy’s Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Neurelis Inc-製薬・医療分野:企業M&A・提携分析
    Summary Neurelis Inc. (Neurelis) is a specialty pharmaceutical company, which develops medicines to target unmet medical need in epilepsy and acute anxiety episodes. The company's product portfolio includes NRL-1 (intranasal diazepam), a proprietary formulation, for epilepsy in pediatric and adult p …
  • ConocoPhillips (COP):電力:M&Aディール及び事業提携情報
    Summary ConocoPhillips is an independent upstream oil and gas company. The company explore for, produce, transport and market crude oil, bitumen, natural gas, liquefied natural gas (LNG) and natural gas liquids across the world. It has assets across North America, Europe, Asia and Australia. Its ass …
  • Quest Diagnostics Inc (DGX):製薬・医療:M&Aディール及び事業提携情報
    Summary Quest Diagnostics Inc (Quest Diagnostics) is a provider of diagnostic information services to patients and physicians through a chain of laboratories and company-owned patient service centers. It offers comprehensive range of services including clinical testing with gene-based and other esot …
  • Cooper-Standard Holdings Inc.:企業の戦略・SWOT・財務分析
    Cooper-Standard Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Cooper-Standard Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Tillotts Pharma AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Tillotts Pharma AG (Tillotts) a subsidiary of Zeria Pharmaceutical Co Ltd is a healthcare solution provider that develops, licenses and markets pharmaceutical products, medical devices and diagnostics in the field of gastroenterology. The company’s products are used for the treatment of vari …
  • Sumitomo Bakelite Co Ltd (4203):企業の財務・戦略的SWOT分析
    Sumitomo Bakelite Co Ltd (4203) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Kyokuyo Co., Ltd.:企業の戦略・SWOT・財務分析
    Kyokuyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kyokuyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • James Fisher and Sons Plc (FSJ):電力:M&Aディール及び事業提携情報
    Summary James Fisher and Sons Plc (James Fisher) is a service provider for global marine industry and a specialist supplier of engineering services to the energy industry. The company provides comprehensive services such as design and engineering; inspection and monitoring; lifting and handling; mar …
  • IBC Solar AG:企業の戦略的SWOT分析
    IBC Solar AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • DHX Media Ltd.:企業のM&A・事業提携・投資動向
    DHX Media Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's DHX Media Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆